Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERKLIN 1
NL-OMON51269Phase 2Not yet recruiting
- Sponsor
- 4SC AG
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Domatinostat and avelumab in Merkel cell carcinoma (MCC), sponsored by 4SC AG. Primary endpoint: Confirmed objective response rate. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
Domatinostatavelumab
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NL-OMON51269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51269.